NXL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (14 May 2024 @ 16:00):

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China...

Stats
Today's Volume	78 561.00
Average Volume	849 296
Market Cap	10.19M
EPS	$0 ( 2024-05-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.17
ATR14	$0.0180 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2022-09-16	White Mark	Buy	25 000	Common stock warrants
2022-09-16	Owens David	Buy	2 500	Common stock warrants
2022-09-16	Kazden Alan	Buy	2 500	Common stock warrants
2022-09-28	Elson Marilyn	Buy	9 500	Common stock warrants
2022-09-16	Morad Rick	Buy	2 500	Common Stock

INSIDER POWER
100.00
Last 96 transactions
Buy: 374 963 \| Sell: 780 427

Nexalin Technology, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nexalin Technology, Inc. Financials

Annual	2023
Revenue:	$110 748
Gross Profit:	$-1.30M (-1 176.41 %)
EPS:	$-0.630

FY	2023
Revenue:	$110 748
Gross Profit:	$-1.30M (-1 176.41 %)
EPS:	$-0.630

FY	2022
Revenue:	$1.32M
Gross Profit:	$958 145 (72.51 %)
EPS:	$-0.260

FY	2021
Revenue:	$144 065
Gross Profit:	$122 623 (85.12 %)
EPS:	$-0.940

Financial Reports:

No articles found.

Nexalin Technology, Inc.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.